All In Biotech

Drug Trial Radar · NCT04977024

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

63

Actual

Start

Sep 27, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
GeoVax, Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The immune system is stimulated to produce antibodies against SARS-CoV-2 that would block the virus from entering healthy cells. The immune system also grows new disease fighting T cells that can recognize and destroy infected cells. Giving GEO-CM04S1 after cellular therapy may work better in reducing the chances of contracting coronavirus disease 2019 (COVID-19) or developing a severe form of COVID-19 disease in patients with blood cancer compared to SOC mRNA SARS-CoV-2 vaccine.

Conditions

  • COVID-19 Infection
  • Hematopoietic and Lymphoid System Neoplasm
  • Leukemia
  • Lymphoma
  • Plasma Cell Myeloma

Interventions

  • COVID-19 VaccineBiological

    Receive SOC mRNA SARS-CoV-2 vaccine IM

  • Diagnostic Laboratory Biomarker AnalysisOther

    Correlative studies

  • Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Biological

    Given IM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biological responseTime frame: At 28 days post the second vaccine injection

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California

  • Johns Hopkins University

    Baltimore, Maryland

  • U Mass Chan Medical School

    Worcester, Massachusetts

  • SUNY-Stony Brook

    Stony Brook, New York

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina

  • Fred Hutchinson Cancer Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.